Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial With Medico-economic Evaluation of the Treatment.
Latest Information Update: 03 Dec 2020
At a glance
- Drugs Prednisone (Primary) ; Rituximab (Primary)
- Indications Bullous pemphigoid
- Focus Adverse reactions; Therapeutic Use
- Acronyms LTFURITUX3
- 01 Jun 2020 Status changed from recruiting to completed.
- 27 Dec 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified De 2018 ).
- 02 Nov 2018 New trial record